About Us


Related Links



Impact


Our major findings bring benefit to society, both in the UK and throughout the world. Explore our impact in the following case studies.


Preventing bone loss in patients treated for breast cancer

Our research into the link between breast cancer and bone loss led to changes in international guidelines and treatment

Almost 30,000 postmenopausal women in the UK develop breast cancer each year. Aromatase inhibitors (AIs) are a class of drug that significantly improve their survival rate.

Research undertaken by the University of Manchester confirmed, however... Read More

Improving outcomes of women diagnosed with and at increased risk of breast cancer

Over 1.5 million women who develop breast cancer each year have benefited from our research into treatment and prevention

Breast cancer is the most common cause of cancer and cancer mortality in women worldwide.

Research conducted at The University of Manchester on the treatment and prevention of breast cancer has benefited over 1.5 million women... Read More

The Development and Translation of Tamoxifen to the Clinic in Manchester

The first clinical trial of the drug was begun at the Christie Hospital, Manchester in December 1969

The Development and Translation of Tamoxifen to the Clinic in Manchester... Further Reading

Seminars


Date:  02 July 201916:00
Speaker:  Maria Vivanco
From:  CIC bioGUNE, Bilbao, Spain
Title:  Endocrine resistance in breast cancer
Host:  Rob Clarke
 
Date:  10 September 201916:00
Speaker:  Carla van Gils
From:  University Medical Centre, Utrecht, The Netherlands
Title:  Imaging in breast cancer detection
Host:  Sue Astley
 
Date:  31 October 201916:00
Speaker:  Karin de Visser
From:  NKI, Amsterdam, The Netherlands
Title:  Impact of the immune system on metastatic breast cancer and therapy response
Host:  Rob Clarke
 
Date:  07 November 201916:00
Speaker:  Cristina Branco
From:  Queen's University Belfast
Title:  TBA
Host:  Ahmet Ucar